secwatch.observer — SEC 8-K summary
======================================

Issuer:     Envoy Medical, Inc. (COCH)
CIK:        0001840877
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001213900-25-107898
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Envoy Medical eliminates $32M debt, gets FDA approval to expand cochlear implant trial
--------------------------------------------------------------------------------

- Extinguished over $32 million in debt, strengthening balance sheet without equity issuance.
- Post-quarter: FDA approved expansion of pivotal clinical trial to final stage; three patients enrolled.
- Closed up to $16 million registered direct offering priced at-the-market under Nasdaq rules.
- Q3 net revenue $42,000; R&D expenses $2.7M; cash $3.556M as of Sept. 30, 2025.
- Expanded global patent portfolio with four new patents in U.S., Europe, and Australia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840877/000121390025107898/0001213900-25-107898-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840877/000121390025107898/ea0264709-8k_envoy.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-107898

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer